Cargando…

Ease of Use, Preference, and Safety of the Recombinant Human Growth Hormone Disposable Pen Compared with the Reusable Device: A Multicenter, Single-Arm, Open-Label, Switch-Over, Prospective, Phase IV Trial

PURPOSE: To assess the usability and safety of the disposable pen compared to those of reusable devices in patients receiving recombinant human growth hormone (rhGH) treatment. PATIENTS AND METHODS: This study was a multicenter, single-arm, open-label, switch-over, prospective, Phase IV trial. After...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Ji-Eun, Kim, Se Young, Yoo, Jae-Ho, Hwang, Il Tae, Lim, Jung Sub, Yi, Kyung Hee, Rhie, Young-Jun, Lee, Gyung Min, Nam, Hyo-Kyoung, Chae, Hyun Wook, Kim, Eun Young, Cheon, Chong Kun, Lee, Jieun, Shim, Young Suk, Lee, YuJin, Hwang, Jin Soon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6929929/
https://www.ncbi.nlm.nih.gov/pubmed/31908426
http://dx.doi.org/10.2147/PPA.S229536
_version_ 1783482795978391552
author Lee, Ji-Eun
Kim, Se Young
Yoo, Jae-Ho
Hwang, Il Tae
Lim, Jung Sub
Yi, Kyung Hee
Rhie, Young-Jun
Lee, Gyung Min
Nam, Hyo-Kyoung
Chae, Hyun Wook
Kim, Eun Young
Cheon, Chong Kun
Lee, Jieun
Shim, Young Suk
Lee, YuJin
Kim, Eun Young
Hwang, Jin Soon
author_facet Lee, Ji-Eun
Kim, Se Young
Yoo, Jae-Ho
Hwang, Il Tae
Lim, Jung Sub
Yi, Kyung Hee
Rhie, Young-Jun
Lee, Gyung Min
Nam, Hyo-Kyoung
Chae, Hyun Wook
Kim, Eun Young
Cheon, Chong Kun
Lee, Jieun
Shim, Young Suk
Lee, YuJin
Kim, Eun Young
Hwang, Jin Soon
author_sort Lee, Ji-Eun
collection PubMed
description PURPOSE: To assess the usability and safety of the disposable pen compared to those of reusable devices in patients receiving recombinant human growth hormone (rhGH) treatment. PATIENTS AND METHODS: This study was a multicenter, single-arm, open-label, switch-over, prospective, Phase IV trial. After screening, eligible patients who were previously treated with rhGH using a reusable device were enrolled to receive treatment with the disposable pen for 8 weeks. The ease of use, preference, and tolerability of the disposable pen compared to those of the reusable device were assessed by the subjects and/or their caregivers using a questionnaire. Adverse events were evaluated by the investigators. RESULTS: Of 116 subjects enrolled in this study, 115 received treatment with the disposable pen and 109 completed the study. The mean age of the subjects was 9.4 years. Compared to the previous reusable device, the disposable pen was assessed as significantly easier to use (mean value 7.88, 95% confidence interval (CI) [7.45–8.30] on a numerical scale ranging from 0 (far less easy) to 10 (far easier)). Furthermore, the percentage of subjects who preferred the disposable pen to the previously used reusable device was 75.7% (95% CI [67.6%–83.8%]). The percentages of subjects who rated pain and discomfort at the injection site as “not at all” were higher after using the disposable pen compared to the reusable device. No specific safety concerns were identified. CONCLUSION: The disposable pen is easier to use than the reusable devices and is preferred by approximately 75% of patients receiving rhGH treatment. Moreover, the disposable pen is safe and acceptable. Therefore, it could be a good alternative to reusable devices. The disposable pen is expected to provide benefits to patients receiving rhGH treatment. CLINICALTRIALS.GOV IDENTIFIER: NCT03015909.
format Online
Article
Text
id pubmed-6929929
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-69299292020-01-06 Ease of Use, Preference, and Safety of the Recombinant Human Growth Hormone Disposable Pen Compared with the Reusable Device: A Multicenter, Single-Arm, Open-Label, Switch-Over, Prospective, Phase IV Trial Lee, Ji-Eun Kim, Se Young Yoo, Jae-Ho Hwang, Il Tae Lim, Jung Sub Yi, Kyung Hee Rhie, Young-Jun Lee, Gyung Min Nam, Hyo-Kyoung Chae, Hyun Wook Kim, Eun Young Cheon, Chong Kun Lee, Jieun Shim, Young Suk Lee, YuJin Kim, Eun Young Hwang, Jin Soon Patient Prefer Adherence Original Research PURPOSE: To assess the usability and safety of the disposable pen compared to those of reusable devices in patients receiving recombinant human growth hormone (rhGH) treatment. PATIENTS AND METHODS: This study was a multicenter, single-arm, open-label, switch-over, prospective, Phase IV trial. After screening, eligible patients who were previously treated with rhGH using a reusable device were enrolled to receive treatment with the disposable pen for 8 weeks. The ease of use, preference, and tolerability of the disposable pen compared to those of the reusable device were assessed by the subjects and/or their caregivers using a questionnaire. Adverse events were evaluated by the investigators. RESULTS: Of 116 subjects enrolled in this study, 115 received treatment with the disposable pen and 109 completed the study. The mean age of the subjects was 9.4 years. Compared to the previous reusable device, the disposable pen was assessed as significantly easier to use (mean value 7.88, 95% confidence interval (CI) [7.45–8.30] on a numerical scale ranging from 0 (far less easy) to 10 (far easier)). Furthermore, the percentage of subjects who preferred the disposable pen to the previously used reusable device was 75.7% (95% CI [67.6%–83.8%]). The percentages of subjects who rated pain and discomfort at the injection site as “not at all” were higher after using the disposable pen compared to the reusable device. No specific safety concerns were identified. CONCLUSION: The disposable pen is easier to use than the reusable devices and is preferred by approximately 75% of patients receiving rhGH treatment. Moreover, the disposable pen is safe and acceptable. Therefore, it could be a good alternative to reusable devices. The disposable pen is expected to provide benefits to patients receiving rhGH treatment. CLINICALTRIALS.GOV IDENTIFIER: NCT03015909. Dove 2019-12-20 /pmc/articles/PMC6929929/ /pubmed/31908426 http://dx.doi.org/10.2147/PPA.S229536 Text en © 2019 Lee et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Lee, Ji-Eun
Kim, Se Young
Yoo, Jae-Ho
Hwang, Il Tae
Lim, Jung Sub
Yi, Kyung Hee
Rhie, Young-Jun
Lee, Gyung Min
Nam, Hyo-Kyoung
Chae, Hyun Wook
Kim, Eun Young
Cheon, Chong Kun
Lee, Jieun
Shim, Young Suk
Lee, YuJin
Kim, Eun Young
Hwang, Jin Soon
Ease of Use, Preference, and Safety of the Recombinant Human Growth Hormone Disposable Pen Compared with the Reusable Device: A Multicenter, Single-Arm, Open-Label, Switch-Over, Prospective, Phase IV Trial
title Ease of Use, Preference, and Safety of the Recombinant Human Growth Hormone Disposable Pen Compared with the Reusable Device: A Multicenter, Single-Arm, Open-Label, Switch-Over, Prospective, Phase IV Trial
title_full Ease of Use, Preference, and Safety of the Recombinant Human Growth Hormone Disposable Pen Compared with the Reusable Device: A Multicenter, Single-Arm, Open-Label, Switch-Over, Prospective, Phase IV Trial
title_fullStr Ease of Use, Preference, and Safety of the Recombinant Human Growth Hormone Disposable Pen Compared with the Reusable Device: A Multicenter, Single-Arm, Open-Label, Switch-Over, Prospective, Phase IV Trial
title_full_unstemmed Ease of Use, Preference, and Safety of the Recombinant Human Growth Hormone Disposable Pen Compared with the Reusable Device: A Multicenter, Single-Arm, Open-Label, Switch-Over, Prospective, Phase IV Trial
title_short Ease of Use, Preference, and Safety of the Recombinant Human Growth Hormone Disposable Pen Compared with the Reusable Device: A Multicenter, Single-Arm, Open-Label, Switch-Over, Prospective, Phase IV Trial
title_sort ease of use, preference, and safety of the recombinant human growth hormone disposable pen compared with the reusable device: a multicenter, single-arm, open-label, switch-over, prospective, phase iv trial
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6929929/
https://www.ncbi.nlm.nih.gov/pubmed/31908426
http://dx.doi.org/10.2147/PPA.S229536
work_keys_str_mv AT leejieun easeofusepreferenceandsafetyoftherecombinanthumangrowthhormonedisposablepencomparedwiththereusabledeviceamulticentersinglearmopenlabelswitchoverprospectivephaseivtrial
AT kimseyoung easeofusepreferenceandsafetyoftherecombinanthumangrowthhormonedisposablepencomparedwiththereusabledeviceamulticentersinglearmopenlabelswitchoverprospectivephaseivtrial
AT yoojaeho easeofusepreferenceandsafetyoftherecombinanthumangrowthhormonedisposablepencomparedwiththereusabledeviceamulticentersinglearmopenlabelswitchoverprospectivephaseivtrial
AT hwangiltae easeofusepreferenceandsafetyoftherecombinanthumangrowthhormonedisposablepencomparedwiththereusabledeviceamulticentersinglearmopenlabelswitchoverprospectivephaseivtrial
AT limjungsub easeofusepreferenceandsafetyoftherecombinanthumangrowthhormonedisposablepencomparedwiththereusabledeviceamulticentersinglearmopenlabelswitchoverprospectivephaseivtrial
AT yikyunghee easeofusepreferenceandsafetyoftherecombinanthumangrowthhormonedisposablepencomparedwiththereusabledeviceamulticentersinglearmopenlabelswitchoverprospectivephaseivtrial
AT rhieyoungjun easeofusepreferenceandsafetyoftherecombinanthumangrowthhormonedisposablepencomparedwiththereusabledeviceamulticentersinglearmopenlabelswitchoverprospectivephaseivtrial
AT leegyungmin easeofusepreferenceandsafetyoftherecombinanthumangrowthhormonedisposablepencomparedwiththereusabledeviceamulticentersinglearmopenlabelswitchoverprospectivephaseivtrial
AT namhyokyoung easeofusepreferenceandsafetyoftherecombinanthumangrowthhormonedisposablepencomparedwiththereusabledeviceamulticentersinglearmopenlabelswitchoverprospectivephaseivtrial
AT chaehyunwook easeofusepreferenceandsafetyoftherecombinanthumangrowthhormonedisposablepencomparedwiththereusabledeviceamulticentersinglearmopenlabelswitchoverprospectivephaseivtrial
AT kimeunyoung easeofusepreferenceandsafetyoftherecombinanthumangrowthhormonedisposablepencomparedwiththereusabledeviceamulticentersinglearmopenlabelswitchoverprospectivephaseivtrial
AT cheonchongkun easeofusepreferenceandsafetyoftherecombinanthumangrowthhormonedisposablepencomparedwiththereusabledeviceamulticentersinglearmopenlabelswitchoverprospectivephaseivtrial
AT leejieun easeofusepreferenceandsafetyoftherecombinanthumangrowthhormonedisposablepencomparedwiththereusabledeviceamulticentersinglearmopenlabelswitchoverprospectivephaseivtrial
AT shimyoungsuk easeofusepreferenceandsafetyoftherecombinanthumangrowthhormonedisposablepencomparedwiththereusabledeviceamulticentersinglearmopenlabelswitchoverprospectivephaseivtrial
AT leeyujin easeofusepreferenceandsafetyoftherecombinanthumangrowthhormonedisposablepencomparedwiththereusabledeviceamulticentersinglearmopenlabelswitchoverprospectivephaseivtrial
AT kimeunyoung easeofusepreferenceandsafetyoftherecombinanthumangrowthhormonedisposablepencomparedwiththereusabledeviceamulticentersinglearmopenlabelswitchoverprospectivephaseivtrial
AT hwangjinsoon easeofusepreferenceandsafetyoftherecombinanthumangrowthhormonedisposablepencomparedwiththereusabledeviceamulticentersinglearmopenlabelswitchoverprospectivephaseivtrial